Figure 1 Gliomas—genetic landscape and biomarkers

Slides:

Advertisements

Similar presentations

HKS Tumore HKS Tumore Epigenetics in glioma - MGMT, ABCB1 and ABCG2 methylation in glioma Moritz C. Oberstadt, PhD.

Advertisements

Molecular Biomarkers & Targets an overview Michael Messenger NIHR Diagnostic Evidence Co-Operative & Leeds Cancer Research UK Centre.

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Advances in Translational Research in Neuro-oncology.

Nat. Rev. Neurol. doi:10/1038/nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Nephrol. doi: /nrneph

Figure 4 Progression-free survival, according to treatment group

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

Figure 2 Response after initial increase in total tumour burden

Nat. Rev. Clin. Oncol. doi: /nrclinonc

The Immune System. The Immune System Adaptive Immune Response.

Figure 2 The US Centers for Disease Control and

Figure 4 Time course of the development of physiological changes

Volume 71, Issue 2, Pages (February 2017)

of different experimental arthritis models

Figure 2 Exosome composition

Figure 3 Risk-adapted and response-adapted

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Neurol. doi: /nrneurol

Figure 2 Systemic immune responses to cryptococcal antigen

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Signalling pathways and physiological domains that are

Figure 3 Altered adaptive immune functions after sepsis

Figure 3 Molecular subgroups of glioblastoma,

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Postulated mechanisms of action of PD‑1, PD‑L1 and PD‑L2

Management of Glioblastoma

Focus on central nervous system neoplasia

Figure 7 Clinical options for HCC therapy

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Proportion of patients for whom NEDA

Basics of Immunotherapy Potential Therapeutic Targets.

Figure 5 Classification of immunotherapies

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Figure 1 Diagnostic tiers of Parkinson disease as single disease

Figure 6 Combination therapy for HCC

Nat. Rev. Urol. doi: /nrurol

Figure 2 Schema for the phase II Randomized Observation versus

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Principles of therapeutic ultrasound

Figure 2 Altered innate immune functions after sepsis

Figure 1 The dynamic nature of resistance mechanisms can be

CDK4/6 Biomarkers: Issues and Opportunities

Nat. Rev. Neurol. doi: /nrneurol

Figure 1 Evolution of multiple sclerosis

Figure 5 The mechanism underlying epithelial-to-mesenchymal

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Biomarkers associated with different clinical phases in MS

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Logistical requirements for autologous

Figure 3 Potential interplay between physiological

Nat. Rev. Endocrinol. doi: /nrendo

Nat. Rev. Urol. doi: /nrurol

Figure 3 Overall survival, according to treatment group

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Figure 1 Mechanisms of action of immunotherapy modalities

CDK4/6 Biomarkers: Issues and Opportunities

Figure 3 Rett syndrome severity and age at diagnosis by mutation type

Nat. Rev. Neurol. doi: /nrneurol

Figure 4 Molecular signalling and immunological

Presentation transcript:

Figure 1 Gliomas—genetic landscape and biomarkers Figure 1 | Gliomas—genetic landscape and biomarkers. Schematic sketch of the relationship of oligodendroglial and astrocytic tumours (not addressing the issue of oligoastrocytoma) to the soluble, circulating biomarkers that are likely to be developed as elements of clinical trials for prognosis and disease monitoring, so as to to detect therapeutic efficacy, tumour progression, or adaptation to therapy. Markers can either be relevant to prognosis (indicated with 'P'), or relate to therapeutic decisions ('T'). For example, MGMT methylation determines the use of temozolomide, and PD1–PDL1 relates to the potential use of immune checkpoint inhibitors. The vertical arrows indicate progression along the WHO grade. Yellow indicates the tumour type (according to the WHO classification), and blue indicates potential circulating biomarkers and the information they contain; green indicates potential therapeutic relevance. Abbreviations: ctDNA, circulating tumour DNA; MGMT, O6-methylguanine-DNA methyltransferase; PD1, programmed cell death protein 1; PDL1, programmed cell death 1 ligand 1; sGBM, secondary glioblastoma. Westphal, M. & Lamszus, K. (2015) Circulating biomarkers for gliomas Nat. Rev. Neurol. doi:10.1038/nrneurol.2015.171